Columbia University researchers led by Michel Sadelain reported development of HLA‑independent T cell (HIT) receptors that confer extreme sensitivity to low‑density tumor antigens. Preclinical studies published in Science showed CD70‑HIT cells eradicated kidney, ovarian, and pancreatic tumors in models that resists conventional CAR‑T approaches. HIT cells combine programmable CAR‑like engineering with the native sensitivity of T‑cell receptors, enabling detection of "stealth" targets with few surface molecules. Authors argue this expands the universe of targetable solid tumors and offers a strategy to overcome antigen heterogeneity. The work is preclinical but represents a potential platform advance for solid‑tumor cell therapies; next steps include safety profiling, manufacturability assessments, and translation into early‑phase clinical testing.